SMS Pharmaceuticals Passes USFDA Inspection at Vizag API Facility with Minor Observation
Key Insights
SMS Pharmaceuticals (search) successfully completed a USFDA (search) inspection at its Visakhapatnam API manufacturing facility from December 8-12, 2025, receiving only one minor Form 483 observation.
The observation was procedural in nature and not related to data integrity, with the company planning to respond within the stipulated timeframe.
This marks the fourth inspection for the 3,000 KL flagship facility and the twelfth across SMS Pharmaceuticals (search)' manufacturing network, reinforcing its regulatory compliance record.
SMS Pharmaceuticals (search) Limited has successfully completed a US Food and Drug Administration (USFDA (search)) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Visakhapatnam, Andhra Pradesh, with only one minor procedural observation.
The inspection, conducted from December 8 to December 12, 2025, concluded with a single minor Form 483 observation that the company confirmed is procedural in nature and not related to data integrity. SMS Pharmaceuticals (search) will submit its response to the USFDA (search) within the stipulated timeframe.
Facility Overview and Regulatory Standing
The Vizag facility represents SMS Pharmaceuticals (search)' flagship 3,000 KL multipurpose API plant, specifically designed for the production of niche, large-volume molecules. The facility maintains multiple international regulatory approvals, including USFDA (search), WHO-GMP (search), EU-GMP (search), KFDA (search), CDSCO (search), and PMDA certifications.
This successful inspection marks a significant milestone in the company's regulatory compliance history, representing the fourth inspection for this particular facility and the twelfth across SMS Pharmaceuticals (search)' entire manufacturing network, which includes two audits of their Central Laboratory Analytical Services (CLAS).
Management Response
P. Vamsi Krishna, Executive Director of SMS Pharmaceuticals (search), emphasized the significance of the inspection outcome. "The successful completion of this USFDA (search) inspection underscores our strong focus on quality, compliance, and global regulatory excellence," he stated. "This achievement further strengthens our position as a reliable API partner to global pharmaceutical companies."
Krishna highlighted that this milestone supports the continued supply of high-quality APIs to key international markets and reinforces the company's commitment to stringent quality and regulatory compliance standards.
Strategic Implications
The successful inspection outcome positions SMS Pharmaceuticals (search) to maintain its role as a reliable partner to global pharmaceutical companies. The facility's comprehensive regulatory approval portfolio enables the company to serve diverse international markets while maintaining compliance with varying regulatory standards across different jurisdictions.